Effect of G6PD Activity, Mediterranean Mutation and Some Biomarkers on Patients with Diabetes Mellitus

Abdulqader Wael Rasheid; Firas Taher Maher; Akeel Hussein Al-Aisse; Adnan Fadhel Nasseef

doi:doi:10.11648/j.ab.20210903.17

| Peer-Reviewed

Effect of G6PD Activity, Mediterranean Mutation and Some Biomarkers on Patients with Diabetes Mellitus

Abdulqader Wael Rasheid, Firas Taher Maher, Akeel Hussein Al-Aisse, Adnan Fadhel Nasseef

Published in Advances in Biochemistry (Volume 9, Issue 3)

Received: 19 July 2021 Accepted: 7 August 2021 Published: 31 August 2021

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Diabetes mellitus is a metabolic disease belongs to a group of disparate diseases clinically and genetically characterized by increased blood sugar (hyperglycemia) as a result of defect in insulin metabolism. Glucose-6-Phosphate Dehydrogenase (G6PD) (Oxidoreductase, EC 1.1.1.1-49) is one of the most important enzymes of the metabolite, the main enzyme and the key to the Pentose phosphate path way. Unsuitable control of blood glucose decreases G6PD activity and increases diabetes mellitus complications. the This study evaluated effect of Mediterranean mutation which causes decrease G6PD activity on diabetes patients and evaluated the difference of G6PD activity among diabetic and non-diabetic patients, and the impact of hyperglycemia on the G6PD activity and different in G6PD activity in six and age and relation between Calcium and Magnesium with G6PD activity and Mediterranean mutation and found correlative coefficient(r) between G6PD activity in Patient and Blood sugar, Calcium, Magnesium and G6PD activity in healthy people. Asixteen diabetic and non-diabetic subjects were selected from patients 8 to 60 years old. Demographic data including gender, age, height, weight, duration of diabetes mellitus, type and duration of treatment, medical history (especially fauvism) were recorded. Blood pressure and body mass index were also measured. One blood sample was taken from each subject and 5 elements including G6PD presence and activity, fasting plasma glucose, plasma Calcium, Magnesium and DNA was extraction from whole blood and then amplified by polymerase chain reaction (PCR) and later subjected to digestion by restriction enzyme MboII to create restriction fragment length polymorphism (RFLP) to enable the detection of mutation that caused G6PD deficiency namely Mediterranean (Med). G6PD activity was significantly higher in non-diabetic subjects (P<0.05). Within diabetics, G6PD mean activity was significantly higher in non-group (P<0.05) and in subjects with BMI < 25 (P<0.05). G6PD mean activity was significantly higher in non-diabetics than (P<0.01) and Ca, Mg diabetics patients (P<0.05) the Med-G6PD mutation in diabetes patient was more in non-diabetes patient, (47) diabetes patient have Med-G6PD (78.3%) and (15) non diabetes have the mutation (15%) and the G6PD activity was significantly higher with Med-G6PD mutation in in diabetes patient (P<0.05) and non-significantly higher with non-diabetes patient. The Med-G6PD mutation can be used as molecular marker to diagnosis diabetes, Diabetic hyperglycemia may lead to serious complications and decrease G6PD activity. This issue itself aggravates diabetic injury due to inappropriate anti oxidation process. Simultaneous dyslipidemia and obesity may intensify the effect of hyperglycemia and oxidative stress.

Published in	Advances in Biochemistry (Volume 9, Issue 3)
DOI	10.11648/j.ab.20210903.17
Page(s)	82-89
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2021. Published by Science Publishing Group

Keywords

Glucose-6-phosphate Dehydrogenase (G6PD), Diabetes Mellitus, PCR-RFLP, Mediterranean Mutation

References

[1]	WHO (2015); Definition, Diagnosis and classification of diabetes mellitus and complication. part 1: Diagnosis and classification of diabetes mellitus. Department of non-communicable disease surveillance, Genève.
[2]	American Diabetes Association, (2016). “Diagnosis and classification of diabetes mellitus,” Diabetes Care, vol 33, (supplement 1): S62–S98.
[3]	Patlak, M., (2002). New weapons to combat ancient treating diabetes. FASEB, J, 16 (14): 1853.
[4]	Saúl Gómez-Manzo Jaime Marcial-Quino America Vanoye-Carlo, Hugo Serrano-Posada, Daniel Ortega-Cuellar, Abigail González-Valdez, Rosa Angélica Castillo-Rodríguez, Beatriz Hernández-Ochoa, Edgar Sierra-Palacios, Eduardo Rodríguez-Bustamante and Roberto Arreguin-Espinosa. (2015). (Glucose-6-Phosphate Dehydrogenase: Update and Analysis of New Mutations around the World Colombia. s 1. p 2-p 12.
[5]	Beutler, E. 2011., G6PD Deficiency and other enzyme abnormalities. in.: Williams hematology. Med ctext book. edit by Beutler. lichtman, M. A. coller, B. S. and Kipps, T. J. McGraw-Hill. Newyork. chap. 45: 562-583.
[6]	R. Notaro, A. Afolayan, L. Luzzatto. 2010. Human mutations in Glucose-6-phosphate Dehydrogenase reflect evolutionary history. FASEB Journal 14, p (485-494).
[7]	S. Singh, A. Anand, P. K. Srivastava. (2012). Regulation and properties of glucose-6-phosphate dehydrogenase: Areview. International Journal of Plant Physiology and Biochemistry 4 (1), p (1-19).
[8]	Saremi Mohammad Ali, Saremi Mahnaz and Tavallaei Mahmood. (2008). Rapid genomic DNA extraction (RGDE) Forensic Science International: Genetics Supplement Series 1. p 63–65.
[9]	Al-Tu'ma. F. Jawad and William M. Frankool. (2010). Molecular Basis of G6PD Deficiency in Hyperbilirubinemic Neonates in Middle Euphrates Province: Iraq. Karbala J. Med. Vol. 3, No. 3, 4. P (867-881).
[10]	Al-Jumaily Essam F. and Al-Temmemy Rana A.(2009). Identification of mediterranean mutation in the G6PD gene on molecular level in Iraqi population. Biotechnology Research Center (special edition) Vol. 3- No. p (90-99).
[11]	Seri, Ali. (2013). princple of medical genetic. 2^nd edition, home of shuaa to publish and science Aleppo, Syria. page (281-295).
[12]	Cappai G, Songini M, Doria A, CavalleranoJD, Lorenzi M. (2011). Increased prevalence of proliferativeretinopathy in patientswith type1 diabetes who are deficient in glucose-6-phosphate dehydrogenase. Diabetologia. 54: 1539–1542.
[13]	Nkhoma ET, Poole C, Vannappagari V, HallSA, Beutler E. (2009). The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review andmeta-analysis. Blood Cells Mol Dis; 42: 267–278.
[14]	Riyadh. M. Murtadha. 2013. Is There Any Association Between Type 2 Diabetes Mellitus and Biochemical Evidence of Vitamin D Deficiency Karbala Journal of Pharmaceutical Sciences Number 6. p (147-152).
[15]	Ameerah M. Ali Al-Hassan, Reyam A. Hatif, Ruaa H Dhari and Entehaa H. Edan. 2016. Study on Diabetes Mellitus and the Balance of Electrolytes. Journal of Babylon University/Pure and Applied Sciences/ No. (7)/ Vol. (24). P (1947-1953).
[16]	Crawford A, Harris H. 2012. Balancing act: calcium & phosphorus [J]. Nursing, 42 (1): 36-42.
[17]	Hamad NA, Eltayeb LB, Brair SL, Bakheit KH, Hamdan ZK, Omer WH: (2013), a clinical study of serum calcium, phosphorus, Alkaline Phosphatase and Magnesium level in type ІІ Diabetes mellitus among Sudanese population in Khartoum state; Al Neelain in Medical Journal, 3 [10]; 42-50.
[18]	Levy J, Zhu Z, Dunbar JC. (1998). The effect of glucose and calcium on Ca²⁺-adenosine tri phosphatasein pancreatic islets isolated from a normal and a non-insulin-dependent diabetes mellitus rat model. Metabolism. Feb; 47 (2): 185-9.
[19]	Fogh-Andersen N, McNair P, Muller-Petersen J and Madsbad S. (2011). Serum calcium fractions in diabetes mellitus. American Association Journal for Clinical Chemistry. 28: 2073-2076.
[20]	AL-Sammraie Abdilkarim. J. Yehia. (2015). Evaluation of Vitamin D Status in Patients with Type 1 Diabetes Mellitus Al-Mustansiriyah Journal of Science Vol. 26, No 1,. P (15-18).
[21]	FANG Linyan, LI Xueping. 2016. Level of serum phosphorus and adult type 2 diabetes mellitus [J]. Journal of Central South University. Medical Science, 41 (5): 502-506.
[22]	Sung, C. C., Liao, M. T., Lu, K. C., & Wu, C. C. (2012). Role of vitamin D in insulin resistance. BioMed Research International., 357. p: 266-282.
[23]	Noori-Daloii, M. R., et al. (2007)., A comprehensive study on the major mutations in glucose-6-phosphate dehydrogenase deficient polymorphic variants identified in the coastal provinces of Caspian Sea in the north of Iran. ClinBiochem. 40 (9-10): p. 699-704.
[24]	Salim J. Khalaf. 2010." Study of some biochemical markers in diabetic patients. Tikrit Medical Journal. 16 (2): 84-87.
[25]	Nanda, R., Mishra, P. K., Das, U. K., Rout, S. B and panda, A. 2014. Evaluating role of oxidative stress in determining the pathogenesis of Flaciparium malaria induced acute renal failure. Indian J. Clin. Biochem. 19 (1): 93 – 96.
[26]	Ou HY, Yang YC, Wu HT, Wu JS, Lu FH, and Chang CJ. 2011.: Serum fetuin-A concentrations are elevated in subjects with impaired glucose tolerance and newly diagnosed type 2 diabetes. Clin Endocrinol (Oxf).; 75 (4): 450-455.
[27]	Amal R. Farahan and Walla E. Jassem. 2015. The Effect of Age and Gender on Fetuin-A and Some Biochemical parameters in Blood Sera of Iraqi patients with T2DM: A comparative study. Baghdad Science Journal Vol. 12 (1). p (197-203).
[28]	Pinna Antonio et, al.(2011). glucose-6-phosphate dehydrogenase deficiency and diabetes mellitus with severe retinal complications in Sardinian population, Italy. International journal of medical science, vol 10 (13), 1907-1913.
[29]	Mandel, J. L.; Monaco, A. P.; Nilson, D. L.; Schlessinger, D. and Willerd, H. (1992). Genome Analysis and the Human X chromosome. Science 258: 103-109.
[30]	Oppenheim, A., et al. (2013). G6PD Mediterranean accounts for the high prevalence of G6PD deficiency in Kurdish Jews. Hum Genet, 91 (3): p. 293-4.
[31]	Al-Allawi N, Eissa AA, Jubrael JMS, Jamal SAR, Hamamy H. 2010. Prevalence and Molecular Characterization of Glucose-6-Phosphate Dehydrogenase Deficient Variants among the Kurdish population of Northern Iraq. BMC Blood Disorders, 10: 6.
[32]	Al-Hamamy H. A, Th. Kh. Saeed, Alwan. A. S. March 2011. Association of Glucose-6-Phosphate Dehydrogenase Deficiency with Diabetes Mellitus. journal of clinical Volume 2, Issue 2. Pages 110–112.
[33]	Rahimi, Z., et al. 2016. Molecular characterization of glucose-6-phosphate dehydrogenase deficiency in the Kurdish population of Western Iran. Blood Cells Mol Dis, 37 (2): p. 4-66. Mesbah-Namin, S. A., et al. (2012). Three major glucose-6-phosphate dehydrogenase-deficient polymorphic variants identified in Mazandaran state of Iran. Br J Haematol, 117 (3): p. 763-4.
[34]	Saleh Ahmed Bin Amro, Eiman Al Zaabi, Shakir Hussain, Amira Mahmoud Aly, Huda Salman Baqir, Abdul–Hamid Ahmed Zaki, Sultan Ayesh Mohammed Saghir and Narazah Mohammed Yusoff. 2014. Molecular Characterization of Glucose-6-Phosphate Dehydrogenase Deficiency in Abu Dhabi District, United Arab Emirates. Tropical Journal of Pharmaceutical Research 13 (5): 731-737.
[35]	Kurdi-Haidar B, Mason PJ, Berrebi A, et al. (2012). Origin andspread of the glucose-6-hosphate dehydrogenasevariant (G6PD-Mediterranean) in the Middle East. Am J Hum Genet; 47 (6): 1013-9.
[36]	Tishkoff, S. A., et al. (2011). Haplotype diversity and linkage disequilibrium at human G6PD: recent origin of alleles That confer malarial resistance. Science. 293 (5529): p. 455-462.
[37]	Cappellini MD, Fiorelli G (2008) Glucose 6-phosphate dehydrogenase deficiency. Lancet: 371: 64–74.
[38]	Drousiotou, A.; Lefranc, G.; Helal, A. N.; Loiselet, J. and Tishkoff, S. A. (2012). Evidence for balancing selection from nucleotide sequence analyses of human G6PD. Am. J. Hum. Genet, 71: 1112-1128.
[39]	Trask, B. J.; Massa, H.; Kenwrick, S. and Gitschier, J., Am. J. 1991. Hum. Genet. 48, 1–15.
[40]	Persico, M.; Viglietto, G.; Martini, G., Toniolo, D.; Paonessa, G. and Moscatelli, C. (2011). Nucleic Acid Res. 14, 2511-22.
[41]	Marwa. A. T. (Nov, 2015); Evaluation of Calcium, Phosphorus and Magnesium Level Among Vitamin (D) Deficient Diabetes Mellitus Patients in Khartoum State Sch. Bull.; Vol-1, Iss-9. 235-241.

Cite This Article

Plain Text BibTeX RIS

APA Style

Abdulqader Wael Rasheid, Firas Taher Maher, Akeel Hussein Al-Aisse, Adnan Fadhel Nasseef. (2021). Effect of G6PD Activity, Mediterranean Mutation and Some Biomarkers on Patients with Diabetes Mellitus. Advances in Biochemistry, 9(3), 82-89. https://doi.org/10.11648/j.ab.20210903.17

Copy | Download

ACS Style

Abdulqader Wael Rasheid; Firas Taher Maher; Akeel Hussein Al-Aisse; Adnan Fadhel Nasseef. Effect of G6PD Activity, Mediterranean Mutation and Some Biomarkers on Patients with Diabetes Mellitus. Adv. Biochem. 2021, 9(3), 82-89. doi: 10.11648/j.ab.20210903.17

Copy | Download

AMA Style

Abdulqader Wael Rasheid, Firas Taher Maher, Akeel Hussein Al-Aisse, Adnan Fadhel Nasseef. Effect of G6PD Activity, Mediterranean Mutation and Some Biomarkers on Patients with Diabetes Mellitus. Adv Biochem. 2021;9(3):82-89. doi: 10.11648/j.ab.20210903.17

Copy | Download

@article{10.11648/j.ab.20210903.17,
  author = {Abdulqader Wael Rasheid and Firas Taher Maher and Akeel Hussein Al-Aisse and Adnan Fadhel Nasseef},
  title = {Effect of G6PD Activity, Mediterranean Mutation and Some Biomarkers on Patients with Diabetes Mellitus},
  journal = {Advances in Biochemistry},
  volume = {9},
  number = {3},
  pages = {82-89},
  doi = {10.11648/j.ab.20210903.17},
  url = {https://doi.org/10.11648/j.ab.20210903.17},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ab.20210903.17},
  abstract = {Diabetes mellitus is a metabolic disease belongs to a group of disparate diseases clinically and genetically characterized by increased blood sugar (hyperglycemia) as a result of defect in insulin metabolism. Glucose-6-Phosphate Dehydrogenase (G6PD) (Oxidoreductase, EC 1.1.1.1-49) is one of the most important enzymes of the metabolite, the main enzyme and the key to the Pentose phosphate path way. Unsuitable control of blood glucose decreases G6PD activity and increases diabetes mellitus complications. the This study evaluated effect of Mediterranean mutation which causes decrease G6PD activity on diabetes patients and evaluated the difference of G6PD activity among diabetic and non-diabetic patients, and the impact of hyperglycemia on the G6PD activity and different in G6PD activity in six and age and relation between Calcium and Magnesium with G6PD activity and Mediterranean mutation and found correlative coefficient(r) between G6PD activity in Patient and Blood sugar, Calcium, Magnesium and G6PD activity in healthy people. Asixteen diabetic and non-diabetic subjects were selected from patients 8 to 60 years old. Demographic data including gender, age, height, weight, duration of diabetes mellitus, type and duration of treatment, medical history (especially fauvism) were recorded. Blood pressure and body mass index were also measured. One blood sample was taken from each subject and 5 elements including G6PD presence and activity, fasting plasma glucose, plasma Calcium, Magnesium and DNA was extraction from whole blood and then amplified by polymerase chain reaction (PCR) and later subjected to digestion by restriction enzyme MboII to create restriction fragment length polymorphism (RFLP) to enable the detection of mutation that caused G6PD deficiency namely Mediterranean (Med). G6PD activity was significantly higher in non-diabetic subjects (P The Med-G6PD mutation can be used as molecular marker to diagnosis diabetes, Diabetic hyperglycemia may lead to serious complications and decrease G6PD activity. This issue itself aggravates diabetic injury due to inappropriate anti oxidation process. Simultaneous dyslipidemia and obesity may intensify the effect of hyperglycemia and oxidative stress.},
 year = {2021}
}

Copy | Download

TY  - JOUR
T1  - Effect of G6PD Activity, Mediterranean Mutation and Some Biomarkers on Patients with Diabetes Mellitus
AU  - Abdulqader Wael Rasheid
AU  - Firas Taher Maher
AU  - Akeel Hussein Al-Aisse
AU  - Adnan Fadhel Nasseef
Y1  - 2021/08/31
PY  - 2021
N1  - https://doi.org/10.11648/j.ab.20210903.17
DO  - 10.11648/j.ab.20210903.17
T2  - Advances in Biochemistry
JF  - Advances in Biochemistry
JO  - Advances in Biochemistry
SP  - 82
EP  - 89
PB  - Science Publishing Group
SN  - 2329-0862
UR  - https://doi.org/10.11648/j.ab.20210903.17
AB  - Diabetes mellitus is a metabolic disease belongs to a group of disparate diseases clinically and genetically characterized by increased blood sugar (hyperglycemia) as a result of defect in insulin metabolism. Glucose-6-Phosphate Dehydrogenase (G6PD) (Oxidoreductase, EC 1.1.1.1-49) is one of the most important enzymes of the metabolite, the main enzyme and the key to the Pentose phosphate path way. Unsuitable control of blood glucose decreases G6PD activity and increases diabetes mellitus complications. the This study evaluated effect of Mediterranean mutation which causes decrease G6PD activity on diabetes patients and evaluated the difference of G6PD activity among diabetic and non-diabetic patients, and the impact of hyperglycemia on the G6PD activity and different in G6PD activity in six and age and relation between Calcium and Magnesium with G6PD activity and Mediterranean mutation and found correlative coefficient(r) between G6PD activity in Patient and Blood sugar, Calcium, Magnesium and G6PD activity in healthy people. Asixteen diabetic and non-diabetic subjects were selected from patients 8 to 60 years old. Demographic data including gender, age, height, weight, duration of diabetes mellitus, type and duration of treatment, medical history (especially fauvism) were recorded. Blood pressure and body mass index were also measured. One blood sample was taken from each subject and 5 elements including G6PD presence and activity, fasting plasma glucose, plasma Calcium, Magnesium and DNA was extraction from whole blood and then amplified by polymerase chain reaction (PCR) and later subjected to digestion by restriction enzyme MboII to create restriction fragment length polymorphism (RFLP) to enable the detection of mutation that caused G6PD deficiency namely Mediterranean (Med). G6PD activity was significantly higher in non-diabetic subjects (P The Med-G6PD mutation can be used as molecular marker to diagnosis diabetes, Diabetic hyperglycemia may lead to serious complications and decrease G6PD activity. This issue itself aggravates diabetic injury due to inappropriate anti oxidation process. Simultaneous dyslipidemia and obesity may intensify the effect of hyperglycemia and oxidative stress.
VL  - 9
IS  - 3
ER  -

Copy | Download

Author Information

Abdulqader Wael Rasheid

Department of Chemistry, College of Science, University of Tikrit, Tikrit, Iraq
Firas Taher Maher

Department of Chemistry, College of Science, University of Tikrit, Tikrit, Iraq
Akeel Hussein Al-Aisse

Department of Biology, College of Science, University of Tikrit, Tikrit, Iraq
Adnan Fadhel Nasseef

Department of Biology, College of Science, University of Tikrit, Tikrit, Iraq

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Abdulqader Wael Rasheid, Firas Taher Maher, Akeel Hussein Al-Aisse, Adnan Fadhel Nasseef. (2021). Effect of G6PD Activity, Mediterranean Mutation and Some Biomarkers on Patients with Diabetes Mellitus. Advances in Biochemistry, 9(3), 82-89. https://doi.org/10.11648/j.ab.20210903.17

Copy | Download

ACS Style

Abdulqader Wael Rasheid; Firas Taher Maher; Akeel Hussein Al-Aisse; Adnan Fadhel Nasseef. Effect of G6PD Activity, Mediterranean Mutation and Some Biomarkers on Patients with Diabetes Mellitus. Adv. Biochem. 2021, 9(3), 82-89. doi: 10.11648/j.ab.20210903.17

Copy | Download

AMA Style

Abdulqader Wael Rasheid, Firas Taher Maher, Akeel Hussein Al-Aisse, Adnan Fadhel Nasseef. Effect of G6PD Activity, Mediterranean Mutation and Some Biomarkers on Patients with Diabetes Mellitus. Adv Biochem. 2021;9(3):82-89. doi: 10.11648/j.ab.20210903.17

Copy | Download

@article{10.11648/j.ab.20210903.17,
  author = {Abdulqader Wael Rasheid and Firas Taher Maher and Akeel Hussein Al-Aisse and Adnan Fadhel Nasseef},
  title = {Effect of G6PD Activity, Mediterranean Mutation and Some Biomarkers on Patients with Diabetes Mellitus},
  journal = {Advances in Biochemistry},
  volume = {9},
  number = {3},
  pages = {82-89},
  doi = {10.11648/j.ab.20210903.17},
  url = {https://doi.org/10.11648/j.ab.20210903.17},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ab.20210903.17},
  abstract = {Diabetes mellitus is a metabolic disease belongs to a group of disparate diseases clinically and genetically characterized by increased blood sugar (hyperglycemia) as a result of defect in insulin metabolism. Glucose-6-Phosphate Dehydrogenase (G6PD) (Oxidoreductase, EC 1.1.1.1-49) is one of the most important enzymes of the metabolite, the main enzyme and the key to the Pentose phosphate path way. Unsuitable control of blood glucose decreases G6PD activity and increases diabetes mellitus complications. the This study evaluated effect of Mediterranean mutation which causes decrease G6PD activity on diabetes patients and evaluated the difference of G6PD activity among diabetic and non-diabetic patients, and the impact of hyperglycemia on the G6PD activity and different in G6PD activity in six and age and relation between Calcium and Magnesium with G6PD activity and Mediterranean mutation and found correlative coefficient(r) between G6PD activity in Patient and Blood sugar, Calcium, Magnesium and G6PD activity in healthy people. Asixteen diabetic and non-diabetic subjects were selected from patients 8 to 60 years old. Demographic data including gender, age, height, weight, duration of diabetes mellitus, type and duration of treatment, medical history (especially fauvism) were recorded. Blood pressure and body mass index were also measured. One blood sample was taken from each subject and 5 elements including G6PD presence and activity, fasting plasma glucose, plasma Calcium, Magnesium and DNA was extraction from whole blood and then amplified by polymerase chain reaction (PCR) and later subjected to digestion by restriction enzyme MboII to create restriction fragment length polymorphism (RFLP) to enable the detection of mutation that caused G6PD deficiency namely Mediterranean (Med). G6PD activity was significantly higher in non-diabetic subjects (P The Med-G6PD mutation can be used as molecular marker to diagnosis diabetes, Diabetic hyperglycemia may lead to serious complications and decrease G6PD activity. This issue itself aggravates diabetic injury due to inappropriate anti oxidation process. Simultaneous dyslipidemia and obesity may intensify the effect of hyperglycemia and oxidative stress.},
 year = {2021}
}

Copy | Download

TY  - JOUR
T1  - Effect of G6PD Activity, Mediterranean Mutation and Some Biomarkers on Patients with Diabetes Mellitus
AU  - Abdulqader Wael Rasheid
AU  - Firas Taher Maher
AU  - Akeel Hussein Al-Aisse
AU  - Adnan Fadhel Nasseef
Y1  - 2021/08/31
PY  - 2021
N1  - https://doi.org/10.11648/j.ab.20210903.17
DO  - 10.11648/j.ab.20210903.17
T2  - Advances in Biochemistry
JF  - Advances in Biochemistry
JO  - Advances in Biochemistry
SP  - 82
EP  - 89
PB  - Science Publishing Group
SN  - 2329-0862
UR  - https://doi.org/10.11648/j.ab.20210903.17
AB  - Diabetes mellitus is a metabolic disease belongs to a group of disparate diseases clinically and genetically characterized by increased blood sugar (hyperglycemia) as a result of defect in insulin metabolism. Glucose-6-Phosphate Dehydrogenase (G6PD) (Oxidoreductase, EC 1.1.1.1-49) is one of the most important enzymes of the metabolite, the main enzyme and the key to the Pentose phosphate path way. Unsuitable control of blood glucose decreases G6PD activity and increases diabetes mellitus complications. the This study evaluated effect of Mediterranean mutation which causes decrease G6PD activity on diabetes patients and evaluated the difference of G6PD activity among diabetic and non-diabetic patients, and the impact of hyperglycemia on the G6PD activity and different in G6PD activity in six and age and relation between Calcium and Magnesium with G6PD activity and Mediterranean mutation and found correlative coefficient(r) between G6PD activity in Patient and Blood sugar, Calcium, Magnesium and G6PD activity in healthy people. Asixteen diabetic and non-diabetic subjects were selected from patients 8 to 60 years old. Demographic data including gender, age, height, weight, duration of diabetes mellitus, type and duration of treatment, medical history (especially fauvism) were recorded. Blood pressure and body mass index were also measured. One blood sample was taken from each subject and 5 elements including G6PD presence and activity, fasting plasma glucose, plasma Calcium, Magnesium and DNA was extraction from whole blood and then amplified by polymerase chain reaction (PCR) and later subjected to digestion by restriction enzyme MboII to create restriction fragment length polymorphism (RFLP) to enable the detection of mutation that caused G6PD deficiency namely Mediterranean (Med). G6PD activity was significantly higher in non-diabetic subjects (P The Med-G6PD mutation can be used as molecular marker to diagnosis diabetes, Diabetic hyperglycemia may lead to serious complications and decrease G6PD activity. This issue itself aggravates diabetic injury due to inappropriate anti oxidation process. Simultaneous dyslipidemia and obesity may intensify the effect of hyperglycemia and oxidative stress.
VL  - 9
IS  - 3
ER  -

Copy | Download